The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Edible Ginger-derived Nano-lipids Loaded with Doxorubicin as a Novel Drug-delivery Approach for Colon Cancer Therapy
Open accessAbstract
The use of nanotechnology for drug delivery has shown great promise for improving cancer treatment. However, potential toxicity, hazardous environmental effects, issues with large-scale production, and potential excessive costs are challenges that confront their further clinical applications. Here, we describe a nanovector made from ginger-derived lipids that can serve as a delivery platform for the therapeutic agent doxorubicin (Dox) to treat colon cancer. We created nanoparticles from ginger and reassembled their lipids into ginger-derived nanovectors (GDNVs). A subsequent characterization showed that GDNVs were efficiently taken up by colon cancer cells. Viability and apoptosis assays and electric cell-substrate impedance-sensing technology revealed that GDNVs exhibited excellent biocompatibility up to 200 μmol/l; by contrast, cationic liposomes at the same concentrations decreased cell proliferation and increased apoptosis. GDNVs were capable of loading Dox with high efficiency and showed a better pH-dependent drug-release profile than commercially available liposomal-Dox. Modified GDNVs conjugated with the targeting ligand folic acid mediated targeted delivery of Dox to Colon-26 tumors in vivo and enhanced the chemotherapeutic inhibition of tumor growth compared with free drug. Current experiments explore the feasibility of producing nature-derived nanoparticles that are effective as a treatment vehicle while potentially attenuating the issues related to traditional synthetic nanoparticles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Nanoparticle Mediated Tumor Vascular Disruption: A Novel Strategy in Radiation Therapy
Kunjachan, S., Detappe, A., Kumar, R., Ireland, T. J., Cameron, L., Biancur, D. E., Motto‐Ros, V., Sancey, L., Sridhar, S., Makrigiorgos, G. M., et al. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b03073 · Cited by 153
RetractedGlobal patterns and trends in colorectal cancer incidence and mortality
Arnold, M., Sierra, M. S., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2017) · Gut · doi:10.1136/gutjnl-2015-310912 · Cited by 5,228
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Sun, D., Zhuang, X., Xiang, X., Liu, Y., Zhang, S., Liu, C., Barnes, S., Grizzle, W., Miller, D., & Zhang, H.-G. (2010) · Molecular Therapy · doi:10.1038/mt.2010.105 · Cited by 1,572
Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery
Cheng, R., Meng, F., Deng, C., Klok, H.-A., & Zhong, Z. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.084 · Cited by 1,354
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043116 · Cited by 1,248
Bose, S., & Tarafder, S. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2011.11.017 · Cited by 958
Cited by
Plant Exosome-like Nanovesicles: Emerging Therapeutics and Drug Delivery Nanoplatforms
Dad, H. A., Gu, T.-W., Zhu, A.-Q., Huang, L.-Q., & Peng, L.-H. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.030 · Cited by 745
Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth
Cao, M., Yan, H., Han, X., Weng, L., Wei, Q., Sun, X., Lu, W., Wei, Q., Ye, J., Cai, X., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0817-4 · Cited by 552
Hybrid exosomes, exosome-like nanovesicles and engineered exosomes for therapeutic applications
Mondal, J., Pillarisetti, S., Junnuthula, V., Saha, M., Hwang, S. R., Park, I.-K., & Lee, Y.-K. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.027 · Cited by 416
Plant-derived exosome-like nanoparticles and their therapeutic activities
Kim, J., Li, S., Zhang, S., & Wang, J. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2021.05.006 · Cited by 396
Lian, M. Q., Chng, W. H., Liang, J., Yeo, H. Q., Lee, C. K., Belaid, M., Tollemeto, M., Wacker, M. G., Czarny, B., & Pastorin, G. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12283 · Cited by 388
Carbon-based sustainable nanomaterials for water treatment: State-of-art and future perspectives
Nasrollahzadeh, M., Sajjadi, M., Iravani, S., & Varma, R. S. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2020.128005 · Cited by 367
Chen, Q., Li, Q., Liang, Y., Zu, M., Chen, N., Canup, B. S. B., Luo, L., Wang, C., Zeng, L., & Xiao, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.016 · Cited by 361
Self-citationExtracellular Vesicles—Connecting Kingdoms
Woith, E., Fuhrmann, G., & Melzig, M. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225695 · Cited by 329
Plant-derived extracellular vesicles: a novel nanomedicine approach with advantages and challenges
Nemati, M., Singh, B., Mir, R. A., Nemati, M., Babaei, A., Ahmadi, M., Rasmi, Y., Golezani, A. G., & Rezaie, J. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00889-1 · Cited by 307
Zhang, M., Wang, X., Han, M. K., Collins, J. F., & Merlin, D. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0196 · Cited by 302
Self-citationCong, M., Tan, S., Li, S., Gao, L., Huang, L., Zhang, H.-G., & Qiao, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114108 · Cited by 302
You, J. Y., Kang, S. J., & Rhee, W. J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.04.023 · Cited by 291
An efficient method to isolate lemon derived extracellular vesicles for gastric cancer therapy
Yang, M., Liu, X., Luo, Q., Xu, L., & Chen, F. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00656-9 · Cited by 287
Hwang, J.-H., Park, Y.-S., Kim, H.-S., Kim, D.-H., Lee, S.-H., Lee, C.-H., Lee, S.-H., Kim, J.-E., Lee, S., Kim, H. M., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.071 · Cited by 282
Naturally Occurring Exosome Vesicles as Potential Delivery Vehicle for Bioactive Compounds
Akuma, P., Okagu, O. D., & Udenigwe, C. C. (2019) · Frontiers in Sustainable Food Systems · doi:10.3389/fsufs.2019.00023 · Cited by 261
Yang, C., Zhang, M., & Merlin, D. (2018) · Journal of Materials Chemistry B · doi:10.1039/c7tb03207b · Cited by 254
Self-citationAdvances in colon-targeted nano-drug delivery systems: challenges and solutions
Naeem, M., Awan, U. A., Subhan, F., Cao, J., Hlaing, S. P., Lee, J., Im, E., Jung, Y., & Yoo, J.-W. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01219-0 · Cited by 248
Ginger and its active compounds in cancer therapy: From folk uses to nano-therapeutic applications
Mahomoodally, M. F., Aumeeruddy, M. Z., Rengasamy, K. R. R., Roshan, S., Hammad, S., Pandohee, J., Hu, X., & Zengin, G. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.009 · Cited by 178
Recent Advances in Exosome-Based Drug Delivery for Cancer Therapy
Kim, H., Jang, H., Cho, H., Choi, J., Hwang, K. Y., Choi, Y., Kim, S. H., & Yang, Y. (2021) · Cancers · doi:10.3390/cancers13174435 · Cited by 152
Alzahrani, F. A., Khan, M. I., Kameli, N., Alsahafi, E., & Riza, Y. M. (2023) · Biomolecules · doi:10.3390/biom13050839 · Cited by 143
“Ginger-derived EVs also have better pH-dependent drug release properties compared to commercial liposome doxorubicin [73].”
BackgroundPlant-Derived Nanovesicles: Further Exploration of Biomedical Function and Application Potential
Li, A., Li, D., Gu, Y., Liu, R., Tang, X., Zhao, Y., Qi, F., Wei, J., & Liu, J. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.022 · Cited by 137
Strategies for the use of Extracellular Vesicles for the Delivery of Therapeutics
Sil, S., Dagur, R. S., Liao, K., Peeples, E. S., Hu, G., Periyasamy, P., & Buch, S. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09873-y · Cited by 109
Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges
Ubanako, P., Mirza, S., Ruff, P., & Penny, C. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1447953 · Cited by 68
Exosome-like Nanoparticles: A New Type of Nanocarrier
Fernandes, M., Lopes, I., Teixeira, J., Botelho, C., & Gomes, A. C. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867326666190129142604 · Cited by 51
Synergistic vesicle-vector systems for targeted delivery
Marquez, C. A., Oh, C.-I., Ahn, G., Shin, W.-R., Kim, Y.-H., & Ahn, J.-Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02275-6 · Cited by 37
Extracellular vesicle therapy for obesity-induced NAFLD: a comprehensive review of current evidence
Zhang, J., Ma, B., Wang, Z., Chen, Y., Li, C., & Dong, Y. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01292-0 · Cited by 17
Metadata
- Authors
- Zhang, M., Xiao, B., Wang, H., Han, M. K., Zhang, Z., Viennois, E., Xu, C., & Merlin, D.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 24
- Issue
- 10
- Pages
- 1783-1796
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2486594993
- Cited by
- 456
- References
- 51
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.